What's Happening?
Latus Bio, a biotechnology company focused on gene therapies for central nervous system (CNS) and peripheral diseases, has appointed Bethany Mancilla as its new Chief Business Officer. Mancilla brings over 25 years of experience in business development
and corporate strategy, having previously held senior roles at Capsida Biotherapeutics, Cue Biopharma, Kite Pharma, and Amgen. Her appointment comes as Latus Bio prepares to advance its lead candidate, LTS-201, for Huntington's disease into clinical trials. Mancilla's expertise in securing high-value transactions and strategic partnerships is expected to be instrumental in expanding Latus Bio's pipeline and market reach.
Why It's Important?
Mancilla's appointment is significant for Latus Bio as it transitions into a clinical-stage company. Her leadership is anticipated to drive the company's strategic growth, particularly in the competitive field of gene therapy. The development of LTS-201, which targets the genetic mechanisms of Huntington's disease, represents a potentially transformative approach to treatment. Successful advancement of this and other pipeline candidates could position Latus Bio as a leader in the biotechnology sector, attracting further investment and partnerships. This development also highlights the growing importance of gene therapy in addressing unmet medical needs.
What's Next?
Latus Bio is expected to submit an Investigational New Drug (IND) application for LTS-201 in the third quarter of 2026. The company will likely focus on building strategic partnerships to enhance its research and development capabilities. Mancilla's role will be crucial in navigating regulatory pathways and securing collaborations that can accelerate the commercialization of Latus Bio's therapies. The biotechnology industry will be watching closely as Latus Bio progresses its clinical programs and explores new opportunities for growth.
